Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Clopidogrel

Clopidogrel

Plavix

Antiplatelet • P2Y12 inhibitor

Premium
Bleeding

Half-life

6 h

Protein Binding

Metabolized By

CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2C8

External

Drugs.com

Mechanism of Action

Prodrug that irreversibly inhibits P2Y12 ADP receptor on platelets

Indications(4)

Acute coronary syndromes (STEMI, NSTEMI, unstable angina)Coronary artery disease — PCI / stent prophylaxisIschaemic stroke preventionPeripheral arterial disease

Classification

Drug Class

Antiplatelet

Subclass

P2Y12 inhibitor

Brand Names

Plavix

Key Properties

Half-life

6 h

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Clopidogrel Drug Profile | PharmaGraphX